Efficacy and Safety of Omalizumab in Japanese and Korean Patients With Chronic Idopathic Spontaneous Urticaria (CIU CSU: Results from the Phase 3 POLARIS Study. J of Skin 2017, 1 (3.1), s126. https://doi.org/10.25251/skin.1.supp.125.